NUCOG-meeting, November 19 2013

Programme:

10.00 – 10.15: Arrival and coffee

10.15-10.20 Welcome / Introduction (Hans von der Maase)

10.20 – 11.00: Study presentation "*A multicenter, randomized phase II trial of vinflunine/gemcitabine versus carboplatin /gemcitabine as first line treatment in patients with metastatic urothelial carcinoma unfit for cisplatin based chemotherapy due to impaired renal function."*

10.20-10.35 Introduction and background to protocol NUCOG I (Anders Ullén)

10.35-11.00 General study presentation (Karin Holmsten)

11.00 – 11.10: How to include patients? Inclusion and exclusion (Karin Holmsten)

11.10 – 11.20: Dose reduction and serious adverse events (Karin Holmsten)

11.20 – 12.00: Monitoring and CRF (Pia Schönbeck)

12.00 – 13.00: Lunch

13.00 – 13.20: Statistics and randomization (Hemming Johansson)

13.20 – 13.25: Time schedule for study initiation in Sweden (Karin Holmsten)

13.25 - 13.30 Time schedule for study initiation in Denmark (Helle Pappot)

13.30 – 13.35 Time schedule for study initiation in Norway (Lene Ekern Kvavik)

13.35 – 13.50: Other NOCUG activities and NUCOG studies (Helle Pappot)

13.50 – 14.00 Q & A and future steps (Anders Ullén)

14.00 - 14.15 Coffee